Long-Term Soliris Treatment Improves Kidney Function
Biotech Business 2010, Jan 1, 23, 1
-
- $5.99
-
- $5.99
Publisher Description
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The study showed that after 38 weeks of Soliris treatment, all patients with chronic kidney disease (CKD), a clinical consequence of chronic hemolysis, either stabilized or improved. Other studies have shown that kidney disease accounts for 18 percent of deaths among Japanese patients with PNH. (1) In the studied patients, Soliris therapy was also associated with a sustained reduction in hemolysis, which resulted in a further improvement in levels of fatigue, as well as a maintained improvement in anemia and a reduction in transfusion requirements. The data were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in a poster titled "Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study."